Abstract:Xiongjie Jia, &ast Tao Zhang, &ast Junjie Sun, Hengxue Lin, Tianliang Bai, Yating Qiao, Yaxin Li, Gang Li, Guicun Li, Xinyu Peng, Aimin Zhang Department of Gastrointestinal Surgery, Affiliated Hospital of Hebei University, Baoding, People's Republic of China &astThese authors contributed equally to this work Correspondence: Aimin Zhang; Xinyu Peng, Department of Gastrointestinal Surgery, Affiliated Hospital of Hebei University, No. 212 Yu-Hua East Road, Baoding City, Hebei Province, People's Republic of China, Tel +863125983782, Email ; Objective: Thymidine Phosphorylase (TYMP) gene was of potential significance in the process of colorectal cancer (CRC) development and played an important role in capecitabine metabolism. This study was to identify the association between TYMP polymorphism and prognosis of postoperative patients with CRC who received capecitabine-based adjuvant chemotherapy. Methods: A total of 218 patients with CRC who were treated with surgical resection and capecitabine-based adjuvant chemotherapy were included in this study retrospectively. Peripheral blood and peripheral blood mononuclear cell (PBMC) specimen of the patients were collected for the genotyping of TYMP polymorphism and TYMP mRNA expression, respectively. Univariate analysis of genotypes and prognosis was carried out by Kaplan–Meier survival analysis, Cox regression analysis was adopted in multivariate analysis. The mRNA expression of TYMP according to genotype status was analyzed using non-parameter test. Results: Prevalence of rs11479 in TYMP among the 218 patients exhibited that minor allele frequency of rs11479 was 0.20 (GG 141 cases, GA 68 cases and AA 9 cases), which was in accordance with Hardy-Weinberg equilibrium ( P =0.825). Association analysis suggested that the median disease-free survival (DFS) of patients with GG genotype and GA/AA genotype was 3.1 and 6.1 years, respectively ( P =0.004). Furthermore, the median overall survival of patients with GG genotype and GA/AA genotype was 5.0 and 7.0 years, respectively ( P =0.033). Multivariate Cox regression analysis exhibited that rs11479 polymorphism was an independent factor for DFS (HR = 1.64, P =0.009). Additionally, of the 65 PBMC specimens, mRNA expression results indicated that patients with GA/AA genotypes conferred significantly higher mRNA expression of TYMP than that of patients with GG genotype ( P < 0.001). Conclusion: Polymorphism rs11479 in TYMP gene might predict the prognosis of patients with CRC who received capecitabine-based adjuvant chemotherapy through mediation of the mRNA expression of TYMP . The conclusion of this study should be validated in prospective clinical trials subsequently. Keywords: colorectal cancer, adjuvant chemotherapy, capecitabine, prognosis, polymorphism Colorectal cancer (CRC) is one of the most common gastrointestinal tumors worldwide. It is estimated that there are approximately 56,000 new cases and 29,000 new deaths of CRC in China currently. 1 To our knowledge, surgical resection was established to be curable for patients with CRC over the past decades. Unfortunately, approximately 30% of the patients were diagnosed of distant metastasis, thus missing the opportunity for surgical resection. 2 Consequently, almost half of the patients with CRC were able to receive surgical resection clinically. Recent years had witnessed in-depth progress of molecular status in colon cancer or rectal cancer with advanced stage, more and more targeted drugs with different targets of action were developed to provide considerable treatment options, thus bringing survival benefits for the patients consecutively. 3 Nevertheless, meaningful research progress in early-stage and postoperative patients with CRC was still limited comparatively. It was known that IDEA trial was proved to be the significant breakthrough with clinical significance recently, which suggested that 3 months rather than 6 months of adjuvant chemotherapy was recommended for low-risk stage III colon cancer to receive 5-FU related regimens. 4 Conclusions of IDEA trial helped to attenuate the unnecessary side reactions of chemotherapy to some extent in view of the fact that 6 months adjuvant chemotherapy regimens were established to be the standard of care for stage III patients with CRC for decades. 5 The IDEA trial also highlighted more work should be performed to refine the adjuvant chemotherapy for patients with CRC, which was in line with the aim of our study. Besides, with the adequate development of the more sensitive detection techniques, ctDNA had established to be the pot -Abstract Truncated-

Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy

The Predictive Role of MTHFR and ABCG2 Single Nucleotide Polymorphisms on the Outcome of Advanced Colorectal Cancer Treated with First-Line Chemotherapy

The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study

UGT1A1 Predicts Outcome in Colorectal Cancer Treated with Irinotecan and Fluorouracil.

Methylenetetrahydrofolate Reductase C677T Polymorphism Predicts Response and Time to Progression to Gemcitabine-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Chinese Han Population

Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression.

A Cohort Study on the Molecular Mechanism of Distinct Therapeutic Effects and Prognosis in Chinese Colorectal Cancer Patients Who Underwent Neoadjuvant or Surgical Therapies.

ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.

Relationship between single nucleotide polymorphisms of candidate genes and survival of patients with gastric cancer undergoing chemotherapy with capecitabine and paclitaxel

Association Between Polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln Genes and Prognosis of Colorectal Cancer in a Chinese Population

Relationship between Polymorphism of X-ray Repair Cross-complementing Group 1(XRCC1)Genes and Clinical Outcome of Advanced Gastric Cancer Patients Treated with DDP-based Chemotherapy

Targeted Deep Sequencing Reveals APC Mutations As Predictors of Overall Survival in Chinese Colorectal Patients Receiving Adjuvant Chemotherapy.

Study of relationship between polymorphisms of DPYD, ABCB1, GSTP1, ERCC1 genes and clinical features, adverse reactions and prognosis of advanced colonic cancer

Effect of single nucleotide polymorphism of XRCC1 gene on the sensitivity of capecitabine combined with oxaliplatin as first line chemotherapy in gastric cancer patients

The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-Analysis Based on 22 Studies.

Relationship Between Polymorhisms of Related Genes in the Folic Acid Metabolic Pathway and the Survival of Gastric Cancer Patients Treated with Capecitabine Combined with Paclitaxel

Thymidine Phosphorylase Expression and Prognosis in Colorectal Cancer Treated with 5-Fluorouracil-based Chemotherapy: A Meta-Analysis

A Polymorphism in ABCC4 is Related to Efficacy of 5-Fu/capecitabine-based Chemotherapy in Colorectal Cancer Patients

Prediction Value Of Xrcc 1 Gene Polymorphism On The Survival Of Ovarian Cancer Treated By Adjuvant Chemotherapy

Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer

XPG Rs2296147 T>C Polymorphism Predicted Clinical Outcome in Colorectal Cancer